High-Flow Nasal Cannula in COPD: An Update in Current Evidence.

Area of Science:

• Pulmonary Medicine
• Respiratory Care

Background:

• High-flow nasal cannula (HFNC) oxygen therapy is increasingly explored for Chronic Obstructive Pulmonary Disease (COPD).
• Recent literature, including trials and meta-analyses from 2024-2025, investigates HFNC in COPD exacerbations, exercise, and pulmonary rehabilitation.

Purpose of the Study:

• To synthesize recent evidence on HFNC in COPD, focusing on clinical outcomes and physiological mechanisms.
• To contextualize new findings within the existing body of pre-2024 research.

Main Methods:

• Systematic review and synthesis of randomized trials, meta-analyses, and physiological studies published in 2024-2025.
• Analysis of evidence concerning HFNC use in COPD exacerbations, exercise, and pulmonary rehabilitation.

Main Results:

• Recent studies confirm noninvasive ventilation as the standard for COPD exacerbations.
• HFNC shows potential as an alternative or adjunct in specific patient groups, particularly during exercise and pulmonary rehabilitation.
• Significant heterogeneity in study designs and outcomes necessitates careful interpretation.

Conclusions:

• An individualized, context-specific approach to HFNC in COPD is recommended.
• Careful monitoring, flow titration, and timely escalation are crucial for effective HFNC use.
• HFNC demonstrates particular promise in enhancing exercise tolerance and outcomes in pulmonary rehabilitation for COPD.